Autoantibodies against four-and-a-half-LIM domain 1 (FHL1) in inflammatory myopathies: results from an Australian single-centre cohort
Open Access
- 12 January 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (10) , 4145-4154
Abstract
To determine the prevalence and associations of autoantibodies targeting a muscle-specific autoantigen, four-and-a-half-LIM-domain 1 (FHL1), in South Australian patients with histologically-confirmed idiopathic inflammatory myopathies (IIM) and in patients with SSc. Sera from patients with IIM (n = 267) from the South Australian Myositis Database (SAMD), SSc (n = 174) from the Australian Scleroderma Cohort Study (ASCS) and healthy controls (HC, n = 100) were analysed for anti-FHL1 autoantibodies by Enzyme-Linked ImmunoSorbent Assay (ELISA). Autoantibodies to FHL1 were more frequent in patients with IIM (37/267, 13.8%) compared with SSc (12/174, 7%) (P < 0.02) and HC (2/100, 2%) (P < 0.001). The most common IIM subtypes among FHL1+ IIM patients were (32%) and IBM (2/37, 32%). No statistically significant differences in muscular or extra-muscular manifestations of IIM were found when comparing patients who were anti-FHL1+ with their anti-FHL1– counterparts. In 29/37 (78%) anti-FHL1+ patients, no myositis-specific autoantibodies (MSA) were present. In FHL1+ muscle biopsies, there was less frequent infiltration by CD45+ cells (P = 0.04). There was a trend for HLA alleles DRB1*07 and DRB1*15 to be more frequent in anti-FHL1+ compared with anti-FHL1– patients (9/25 vs 19/113, P = 0.09 and 8/25 vs 15/114, P = 0.09, respectively). We report a substantial prevalence (13.8%) of anti-FHL1 autoantibodies in a large cohort of patients with histologically confirmed IIM; 75% of these cases did not have a detectable myositis-specific autoantibody. Anti-FHL1 autoantibodies were also detected in a subgroup of patients with SSc (7%), indicating that anti-FHL1 autoantibodies may not be myositis-specific. The trend towards an HLA-DR association might indicate a specific immune response to the FHL1 protein.Keywords
Funding Information
- The Myositis Association
- the Swedish Research Council (K2014-52X-14045–14-3)
- Swedish Rheumatism Association, King Gustaf V 80 Year Foundation, Konung Gustaf V
- Drottning Victorias Frimurarestiftelse
- Funds at the Karolinska Institutet
- Stockholm County Council
- EU/EFPIA Innovative Medicines Initiative Joint Undertaking (115766)
This publication has 36 references indexed in Scilit:
- Pathophysiology of inflammatory and autoimmune myopathiesLa Presse Médicale, 2011
- Mutations of the FHL1 Gene Cause Emery-Dreifuss Muscular DystrophyThe American Journal of Human Genetics, 2009
- Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathyJournal of Cell Biology, 2008
- Proteomic identification of FHL1 as the protein mutated in human reducing body myopathyJournal of Clinical Investigation, 2008
- Novel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and AutoantibodiesMedicine, 2005
- 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The NetherlandsNeuromuscular Disorders, 2004
- International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset diseaseRheumatology, 2003
- A serologic marker for fetal risk of congenital heart blockArthritis & Rheumatism, 2002
- Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathiesRheumatology, 2001
- A New Approach to the Classification of Idiopathic Inflammatory MyopathyMedicine, 1991